TABLE 4.

Results of the decomposition analysis by cardiovascular and nervous system groups. Minas Gerais, Brazil, 2012–2018.

Therapeutic group a	Drug price effects (P)	Volume effects (V)	Drug-mix effects (D)	Expenditure index (E)b
C—cardiovascular system
C01—cardiac therapy	2.77	0.48	1.15	1.52
C02—anti-hypertensives	0.60	0.55	2.16	0.72
C03—diuretics	1.42	0.57	1.45	1.17
C07—beta-blocking agents	0.75	0.74	1.97	1.08
C08—calcium channel blockers	1.26	1.03	1.07	1.39
C09—agents acting on the renin–angiotensin system	0.82	0.55	1.34	0.60
C10—lipid-modifying agents	1.01	1.47	1.08	1.60
Total	0.98	0.66	1.55	1.01
N—Nervous system c
N02—analgesics	1.85	0.63	0.97	1.12
N03—antiepileptics	1.01	0.77	1.42	1.12
N04—anti-parkinson drugs	0.82	0.93	3.49	2.69
N05—psycholeptics	1.16	0.51	1.55	0.92
N06—psychoanaleptics	1.39	0.95	1.06	1.40
Total	1.36	0.74	1.31	1.32

^aATC, second level.

^b E = P x V x D = $\frac{{\displaystyle \sum P_1{V}_0}}{{\displaystyle \sum P_0{V}_0}}X\frac{{\displaystyle \sum V_1}}{{\displaystyle \sum V_0}}X\frac{\left({\displaystyle \sum P_1{V}_1}/{{\displaystyle \sum V}}_1\right)}{\left({\displaystyle \sum P_1{V}_0}/{\displaystyle \sum V_0}\right)}$

^cN01-anesthetics were only acquired in 2018 and because of that there is no decomposition analyses for this group.